DOI QR코드

DOI QR Code

Association of Arrhythmia in the Elderly Patients on Combination Therapy of CYP3A4 Substrates and Inhibitors with the Korean Claims Data

CYP3A4 기질과 억제제 약물의 병용 고령환자에서 부정맥 부작용 연관성

  • Tae Woo Kim (Department of Clinical Pharmacy, College of Pharmacy, Ajou University) ;
  • Junhyuk Chang (Department of Clinical Pharmacy, College of Pharmacy, Ajou University) ;
  • Eunjung Choo (Department of Biohealth Regulatory Science, College of Pharmacy, Ajou University Graduate School) ;
  • Rae Woong Park (Department of Biomedical Sciences, Ajou University Graduate School of Medicine) ;
  • Sukhyang Lee (Department of Clinical Pharmacy, College of Pharmacy, Ajou University)
  • 김태우 (아주대학교 약학대학) ;
  • 장준혁 (아주대학교 약학대학) ;
  • 추은정 (아주대학교 대학원 바이오헬스규제과학과) ;
  • 박래웅 (아주대학교 대학원 의생명과학과) ;
  • 이숙향 (아주대학교 약학대학)
  • Received : 2023.07.31
  • Accepted : 2023.10.05
  • Published : 2023.12.31

Abstract

Background: Arrhythmia due to QT prolongation is one of the most serious adverse events with drug interactions in the elderly. This study aimed to examine the incidence of arrhythmia in Korean elderly patients who administered both cytochrome P450 3A4 (CYP3A4) substrates and inhibitors. Methods: Patients using CYP3A4 substrate and inhibitor were selected from the 2017 elderly patient dataset (the Korean Health Insurance Review and Assessment Service - Aged Population Sample). Selection criteria were patients with a medication possession ratio over 80%, medication duration of at least 7 days, and a follow-up period of 3 months or more. The patient's basic information is age, gender, health insurance type, and comorbidities. The top 50 drug pairs and comorbidity with high-incidence arrhythmia were presented. Results: In patients with drug combinations for over 7 days, there were 981 incidences of arrhythmia, and 351 incidences in those with combinations for over 30 days. The comorbidities of congestive heart failure and myocardial infarction had a significant association with incidence of arrhythmia. Among patients with 7 days or longer, the drug pairs [substrates-inhibitors] with significant adjusted odds ratio (aOR) were [propranolol-cimetidine] (aOR, 2.25; 95% confidence interval [CI], 1.66-3.04). Among patients with 30 days or longer, the drug pairs with significant aOR were [tramadol-amiodarone] (aOR, 2.87; 95% CI, 1.97-4.19). Conclusions: In elderly patients, the incidence of arrhythmia was high with drug interactions of CYP3A4 substrates and inhibitors. The comorbidity of congestive heart failure was the risk factor.

Keywords

Acknowledgement

본 연구는 2021년 식품의약품안전처의 연구과제(21153 MFDS602)로 수행하였습니다.

References

  1. Statistics Korea. Senior Citizen Statistics Data in 2022. Korea National Statistics Office. 2022. Available from https://kostat.go.kr/board.es?mid=a10301010000&bid=10820&tag=&act=view&list_no=420896&ref_bid, Accessed June 12, 2023 
  2. Yun SH, Kim DS, Chae JM, Choi YM, Cho HJ, Establishment of criteria for managing inappropriate polypharmacy in the elderly. In: Health Insurance Review & Assessment service. 2023. Available from https://repository.hira.or.kr/handle/2019.oak/3086, Accessed June 21, 2023 
  3. Park HY, Sohn HS, Kwon JW. Reviews on the current status and appropriate management of polypharmacy in south korea. Korean J Clin Pharm 2018;28(1):1-9.  https://doi.org/10.24304/kjcp.2018.28.1.1
  4. Seo DS, Yoon JL, Kim SJ, Park JS, Lee WJ, Kim MY. Polypharmacy in older patients admitted to a general hospital. Ann Geriatr Med Res, 2012;16(3):133-40. 
  5. Lee JK. Factors associated with drug misuse behaviors among polypharmacy elderly. Korean Journal of Adult Nursing 2011;23(6):554-63. 
  6. Cheong SJ, Yoon JL, Choi SH, Kim MY, Cho JJ, Ju YS. The effect of polypharmacy on mortality in the elderly. KJFP 2016;6(6):643-50.  https://doi.org/10.21215/kjfp.2016.6.6.643
  7. Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: A scientific statement from the american heart association. Circulation 2020;142(15):e214-33.  https://doi.org/10.1161/CIR.0000000000000905
  8. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med. 1989;111:549-51.  https://doi.org/10.7326/0003-4819-111-7-549
  9. Hussaarts KG, Berger FA, Binkhorst L, et al. The risk of qtc-interval prolongation in breast cancer patients treated with tamoxifen in combination with serotonin reuptake inhibitors. Pharm Res 2020;37:1-8.  https://doi.org/10.1007/s11095-019-2746-9
  10. Khan Q, Ismail M, Haider I, Khan F. Prevalence of qt interval prolonging drug-drug interactions (qt-ddis) in psychiatry wards of tertiary care hospitals in pakistan: A multicenter cross-sectional study. Int J Clin Pharm 2017;39:1256-64.  https://doi.org/10.1007/s11096-017-0532-5
  11. Chastang A, Renet S, Corny J, et al. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other qt-prolonging drugs. Int J Clin Pharm 2019;41:42-8.  https://doi.org/10.1007/s11096-018-0724-7
  12. Momo K, Kobayashi H, Sugiura Y, Yasu T, Koinuma M, Kuroda Si. Prevalence of drug-drug interaction in atrial fibrillation patients based on a large claims data. PLoS One 2019;14(12):e0225297.  https://doi.org/10.1371/journal.pone.0225297
  13. Wei A, Peng J, Gu Z, Li J. Qtc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature. Medicine 2017;96(49):e9071.  https://doi.org/10.1097/MD.0000000000009071
  14. Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and qt prolongation as a commonly assessed cardiac effect-comprehensive overview of clinical trials. BMC Pharmacol Toxicol 2016;17:1-15.  https://doi.org/10.1186/s40360-016-0053-1
  15. Berger FA, van der Sijs H, van Gelder T, Kuijper AF, van den Bemt PM, Becker ML. Comparison of two algorithms to support medication surveillance for drug-drug interactions between qtc-prolonging drugs. Int J Med Inform 2021;145:104329.  https://doi.org/10.1016/j.ijmedinf.2020.104329
  16. Romero L, Cano J, Gomis-Tena J, et al. In silico qt and apd prolongation assay for early screening of drug-induced proarrhythmic risk. J Chem Inf Model 2018;58(4):867-78.  https://doi.org/10.1021/acs.jcim.7b00440
  17. Wisniowska B, Polak S. The role of interaction model in simulation of drug interactions and qt prolongation. Curr Pharmacol Rep 2016;2:339-44.  https://doi.org/10.1007/s40495-016-0075-9
  18. Lee W, Windley MJ, Vandenberg JI, Hill AP. In vitro and in silico risk assessment in acquired long qt syndrome: The devil is in the details. Front Physiol 2017;8:934.  https://doi.org/10.3389/fphys.2017.00934
  19. JE NK, Kim DS, KIM GJ, Lee S. Pharmacodynamic drug-drug interactions considered to be added in the list of contraindications with pharmacological classification in korea. Korean J Clin Pharm 2015;25(2):120-8. 
  20. Flockhart DA, Thacker D, McDonald C, Desta Z. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Available from https://drug-interactions.medicine.iu.edu. Accessed November 1, 2021. 
  21. Cohen N, Modai D, Golik A, Eshkoly M, Theitler J, Scapa E. Cimetidine-related cardiac conduction disturbances and confusion. J Clin Gastroenterol 1989;11(1):68-9.  https://doi.org/10.1097/00004836-198902000-00017
  22. Correa A, Rochlani Y, Aronow WS. Current pharmacotherapeutic strategies for cardiac arrhythmias in heart failure. Expert Opin Pharmacother 2020;21(3):339-52.  https://doi.org/10.1080/14656566.2019.1703950
  23. Fox H, Bitter T, Horstkotte D, Oldenburg O. Sleep-disordered breathing and arrhythmia in heart failure patients. Sleep Med Clin 2017;12(2):229-41.  https://doi.org/10.1016/j.jsmc.2017.01.003
  24. Singh BN. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Heart Fail Rev 2002;7:285-300.  https://doi.org/10.1023/A:1020001912248
  25. Romano IJ, Lippolis A, D'Anna M, Gentile F. Cardiac arrhythmias and acute cerebrovascular events: A case of qt prolongation and torsades de pointes early after right insular stroke. J Stroke Cerebrovasc Dis 2019;28(11):104308.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104308
  26. Ruthirago D, Julayanont P, Tantrachoti P, Kim J, Nugent K. Cardiac arrhythmias and abnormal electrocardiograms after acute stroke. Am J Med Sci 2016;351(1):112-8.  https://doi.org/10.1016/j.amjms.2015.10.020
  27. Koppikar S, Baranchuk A, Guzman JC, Morillo CA. Stroke and ventricular arrhythmias. Int J Cardiol 2013;168(2):653-9.  https://doi.org/10.1016/j.ijcard.2013.03.058
  28. Adejumo AC, Adejumo KL, Akanbi O, et al. Predictors, burden and impact of cardiac arrhythmias among patients hospitalized with end-stage liver disease. Heart Lung 2020;49(1):73-9.  https://doi.org/10.1016/j.hrtlng.2019.07.002
  29. Trevisani F, Merli M, Savelli F, et al. Qt interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003;38(4):461-7.  https://doi.org/10.1016/S0168-8278(03)00057-6
  30. Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Moller S. Prolonged q-tc interval in mild portal hypertensive cirrhosis. J Hepatol 2005;43(4):637-44.  https://doi.org/10.1016/j.jhep.2005.04.015
  31. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in copd: Part 1: Saskatchewan cohort study. Chest 2012;142(2):298-304.  https://doi.org/10.1378/chest.10-2499
  32. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in copd: Part 2: Reassessment in the larger quebec cohort. Chest 2012;142(2):305-11.  https://doi.org/10.1378/chest.11-1597
  33. Rusinowicz T, Zielonka TM, Zycinska K. Cardiac arrhythmias in patients with exacerbation of copd. Clinical Management of Pulmonary Disorders and Diseases 2017;1022:53-62.  https://doi.org/10.1007/5584_2017_41
  34. Han S-J. Amiodarone. International Journal of Arrhythmia 2013;14(2):4-9. 
  35. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol 1990;65(19):42-8.  https://doi.org/10.1016/0002-9149(90)90125-K
  36. Aufderheide TP. Arrhythmias associated with acute myocardial infarction and thrombolysis. Emerg Med Clin North Am 1998;16(3):583-600. https://doi.org/10.1016/S0733-8627(05)70019-5